TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26835603
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) 300 mg natalizumab
Study: 26835603
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) 300 mg natalizumab
Study: 26835603
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) 300 mg natalizumab
Study: 26835603
Drug: Pharmacodynamics (PD)
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacodynamics (PD) response
Study: 22539780
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (STreSS), nine 3.5 h sessions over 4 months
Study: 20679151
Drug: Milk naturally
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk naturally enriched in CLA (4.2%) containing c-9, t-11 providing 1.3 g/d of CLA
Study: 20679151
Drug: Milk enriched
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk enriched with a 4.2% synthetic mixture of t-10, c-12 and c-9, t-11 CLA isomers providing 1.3 g/d of CLA
Study: 20679151
Drug: Untreated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated milk (control) providing 0.2 g/d CLA
Study: 17564282
Drug: 800 mcg
Normalized name: Biotin 800 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mcg nebulized beclomethasone dipropionate once daily (o.d. group)
Study: 17564282
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg nebulized beclomethasone dipropionate twice daily (b.i.d. group)
Study: 10419077
Drug: Felodipine-metoprolol 5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol 5/50 mg
Study: 7759064
Drug: Hyperglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (blood glucose level clamped at 12.2 mmol/l for 4 hours by infusing 20% glucose solution)
Study: 7759064
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control (isotonic saline infusion over 4 hours)
Study: 2185694
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase without KRN 8601 treatment
Study: 311515
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (aortocoronary bypass surgery)
Study: 30972934
Drug: Liraglutide therapy
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide therapy for 16 weeks
Study: 20157905
Drug: Multi-component sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component sleep therapy intervention
Study: 12690368
Drug: Subtenons lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subtenons lidocaine injection (1 mL of 2% lidocaine)
Study: 12690368
Drug: Subtenons lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subtenons lidocaine injection
Study: 8889461
Drug: Pantoprazole 80
Normalized name: pantoprazole 80 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 80 mg
Study: 8791969
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing schedules
Study: 1620911
Drug: Modified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified formulation of inhaled salbutamol using a new inhaler device
Study: 6391830
Drug: Trazodone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (100 to 400 mg daily)
Study: 6391830
Drug: Mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (30 to 120 mg daily)
Study: 30282447
Drug: R-CHOP-14 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP-14 (administered every 2 weeks)
Study: 30282447
Drug: R-CHOP-21 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP-21 (administered every 3 weeks)
Study: 24491414
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml kg(‐1) of 0.15% ropivacaine with 0.1 mg kg(‐1) dexamethasone (Group D)
Study: 24491414
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml kg(‐1) of 0.15% ropivacaine (Group C)
Study: 22348439
Drug: DHA meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA meal (high-oleic sunflower oil enriched with 4.7 g of DHA)
Study: 22348439
Drug: EPA meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA meal (high-oleic sunflower oil enriched with 4.7 g of EPA)
Study: 26201934
Drug: Naso-jejunal (NJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naso-jejunal (NJ) fluid resuscitation using oral hydration solution (ORS: 20 ml/kg bolus and then 3 mL/kg/h)
Study: 26201934
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) fluid resuscitation using Ringer Lactate (RL infusion at same rate)
Study: 26201934
Drug: Naso-jejunal (NJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naso-jejunal (NJ) fluid resuscitation using oral hydration solution (ORS)
Study: 26201934
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) fluid resuscitation using Ringer Lactate (RL)
Study: 22795809
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous bisglycinate chelate, 28 mg per day for 20 days, then 14 mg per day for 40 days (12 patients)
Study: 22795809
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate, 105 mg per day for 60 days (12 patients)
Study: 22795809
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events (AEs) related to treatments
Study: 18039501
Drug: High-dose selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose selenium administration
Study: 18039501
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of selenium
Study: 12034949
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 mg intravenously)
Study: 2254557
Drug: Streptokinase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase treatment
Study: 816842
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of disodium cromoglycate (DSCG)
Study: 816842
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of disodium cromoglycate (DSCG)
Study: 816842
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of disodium cromoglycate (DSCG) four times daily for 2 days
Study: 6453695
Drug: 3% benzoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% benzoyl peroxide gel
Study: 6453695
Drug: 10% benzoyl
Normalized name: BENZOYL PEROXIDE 10 g in 100 g TOPICAL SOAP [Dermaharmony 10% Benzoyl Peroxide Cleansing Bar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% benzoyl peroxide gel
Study: 6453695
Drug: Stronger or
Normalized name: rose water,stronger ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stronger or milder concentration of benzoyl peroxide gel
Study: 29016980
Drug: Stepped Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped Care (initial 20-min of behavioural change counselling, followed by three sessions of Motivational Enhancement Therapy and referral to local alcohol services)
Study: 25633662
Drug: empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin 25 mg/linagliptin 5 mg
Study: 25633662
Drug: empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin 10 mg/linagliptin 5 mg
Study: 22474066
Drug: Torcetrapib 120
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 120 mg once daily for 4 weeks (non-atorvastatin group)
Study: 22474066
Drug: Torcetrapib 120
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 120 mg twice daily for 4 weeks (non-atorvastatin group)
Study: 22474066
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily (control group)
Study: 9727782
Drug: Nebulized magnesium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized magnesium sulphate (3 mL, 3.2% solution, 95 mg)
Study: 9727782
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (3 mL, 2.5 mg)
Study: 3241289
Drug: Methylphenobarbital (MPB)
Normalized name: methylphenobarbital
DrugBank: Methylphenobarbital (DB00849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenobarbital (MPB) 3 x 10 mg/kg on the first day
Study: 31822498
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg) in combination with taselisib (4 mg)
Study: 31822498
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enzalutamide and taselisib
Study: 25451617
Drug: Mother-infant psychoanalytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother-infant psychoanalytic treatment (MIP group)
Study: 16682727
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan 2.3 mg/m2/d on days 1 to 5
Study: 16682727
Drug: Intravenous docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous docetaxel 75 mg/m2 day 1 every 21 days
Study: 10469815
Drug: ZDV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV plus ddI combination therapy
Study: 10469815
Drug: ZDV monotherapy
Normalized name: ZDV
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZDV monotherapy
Study: 10469815
Drug: ddI monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddI monotherapy
Study: 6849160
Drug: Disulfiram 400
Normalized name: disulfiram 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 400 mg/d
Study: 31829248
Drug: Landiolol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Landiolol administration for three days during the perioperative period
Study: 29289374
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg qhs
Study: 27754700
Drug: MPH-MLR (Methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH-MLR (Methylphenidate HCl Extended-Release)
Study: 20537810
Drug: Gradual cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual cessation with nicotine lozenge (via mail)
Study: 15940624
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (peginterferon and lamivudine)
Study: 10100770
Drug: Once-daily 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily 0.75% metronidazole gel 5 g intravaginally for 5 days
Study: 10100770
Drug: Twice-daily 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily 0.75% metronidazole gel 5 g intravaginally for 5 days
Study: 9050699
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone (control group)
Study: 1880221
Drug: Labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100 mg BID to a maximum of 400 mg BID over 6 weeks)
Study: 1880221
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg or less BID)
Study: 29162142
Drug: Concurrent thermochemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent thermochemoradiotherapy (HTCTRT) with locoregional hyperthermia (weekly ×6 during radiotherapy) and concurrent chemoradiotherapy (CTRT) with gemcitabine (400 mg/m2, weekly ×6)
Study: 29162142
Drug: Chemoradiotherapy (CTRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CTRT) alone with gemcitabine (400 mg/m2, weekly ×6)
Study: 16112720
Drug: Cocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (40 mg, IV)
Study: 22818725
Drug: Dried apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried apple (75 g/day)
Study: 20118174
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and sulfonylurea (n = 2227)
Study: 21364503
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 50 mg
Study: 15911461
Drug: Clomiphene plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene plus Metformin
Study: 10087798
Drug: Autogenic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenic therapy
Study: 3102275
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 2 mg
Study: 3102275
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 10 mg
Study: 3102275
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 20 mg
Study: 12616672
Drug: Rofecoxib (250.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (250.0 mg/day for 14 days)
Study: 9794089
Drug: Magnesium orotate
Normalized name: Magnesium orotate
DrugBank: Magnesium orotate (DB13786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium orotate 3 x 1 g
Study: 21099129
Drug: Long-acting octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting octreotide treatment for 3 months before surgery
Study: 21099129
Drug: Long-acting octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting octreotide treatment
Study: 16700996
Drug: Head hypothermia
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head hypothermia treatment
Study: 11250719
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone (LHRH) agonists with low-dose hormone replacement
Study: 29485324
Drug: Protein Supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein Supplement (PRO, 42 g/serving)
Study: 27243611
Drug: Daily music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily music training for 28 days
Study: 22288685
Drug: Four-dose hydrocortisone
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose hydrocortisone regimen (10 + 10 + 5 + 5 mg)
Study: 22288685
Drug: Two-dose hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose hydrocortisone regimen (20 + 0 + 10 + 0 mg)
Study: 18478944
Drug: Sufentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil at 0.3 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Study: 18478944
Drug: Sufentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil at 0.4 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Study: 18478944
Drug: Sufentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil at 0.5 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Study: 15560968
Drug: Ketamine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.6 mg/kg/h)
Study: 12084590
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy (IRT)
Study: 8524979
Drug: Clonidine (CLO)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (CLO) at doses of 1.5 micrograms/kg and 2.5 micrograms/kg
Study: 8524979
Drug: Diazepam (DZP)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZP) at doses of 5 mg and 10 mg
Study: 2405171
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (total mean dose of 54 Gy to the breast)
Study: 2405171
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone (no further treatment)
Study: 415321
Drug: Marijuana (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana (0.7 mg/kg delta‐9‐tetrahydrocannabinol)
Study: 415321
Drug: Ethanol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.0 ml/kg 95% ethanol)
Study: 30165156
Drug: 80% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% reduction of basal insulin applied 40 minutes before exercise (T-40)
Study: 30165156
Drug: 80% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% reduction of basal insulin applied 20 minutes before exercise (T-20)
Study: 30165156
Drug: 80% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% reduction of basal insulin applied at exercise onset (T0)
Study: 21771987
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus triptorelin (3.75 mg intramuscularly at least 1 week before chemotherapy and then every 4 weeks during chemotherapy)
Study: 16766776
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (12 g of BCAAs/day; leucine 54%, isoleucine 19%, valine 27%)
Study: 16766776
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 g of glucose/day)
Study: 9250944
Drug: Ketamine psychedelic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine psychedelic therapy (KPT)
Study: 8222534
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion (20-30 ng kg-1 min)
Study: 3929876
Drug: Feverfew capsules
Normalized name: FEVERFEW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feverfew capsules (freeze dried powder)
Study: 31337448
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (27.5 g whey protein/d, about 2000 kJ/d)
Study: 31337448
Drug: Isoenergetic placebo-products
Normalized name: placebo Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic placebo-products (< 1.5 g protein/d)
Study: 26693964
Drug: STAR intervention
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR intervention (Supporting Treatment Adherence Regimens)
Study: 20580358
Drug: Recombinant hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hCG (250 μg)
Study: 19464177
Drug: Fulvestrant (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (250 mg/month)
Study: 17673609
Drug: Fulvestrant high-dose
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant high-dose (500 mg/month)
Study: 17673609
Drug: Fulvestrant loading-dose
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant loading-dose regimen (250 mg/month plus 500 mg on day 0 and 250 mg on day 14 of month 1)
Study: 16051400
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of pertussis vaccine
Study: 16051400
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of pertussis vaccine
Study: 11966926
Drug: Subgingival water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival water irrigation 2x daily
Study: 10080558
Drug: Fananserin 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fananserin 250 mg b.i.d. over 28 days (with an 8-day escalation)
Study: 7018502
Drug: Colestipol (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (15, 20, and 30 g/day)
Study: 230927
Drug: Clofibrate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate (2 g/day)
Study: 22423411
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment alone
Study: 22423411
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment combined with orthognathic surgery
Study: 22423411
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (orthodontic treatment alone)
Study: 12297762
Drug: Somatostatin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (750 mg)
Study: 12297762
Drug: Gabexate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate (500 mg)
Study: 2148357
Drug: Fosinopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (5 to 40 mg/day)
Study: 29931409
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg three times daily
Study: 20428949
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg and 4 mg
Study: 18322858
Drug: modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: modafinil 400 mg
Study: 18322858
Drug: dextroamphetamine 20
Normalized name: dextroamphetamine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextroamphetamine 20 mg
Study: 18322858
Drug: caffeine 600
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine 600 mg
Study: 12943873
Drug: Gemcabene 150
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcabene 150 mg
Study: 12943873
Drug: Gemcabene 600
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcabene 600 mg
Study: 1707149
Drug: Diphenhydramine syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine syrup plus kaolin-pectin
Study: 6809324
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous hyperalimentation (Control group)